Merck & Co is a global healthcare company that specializes in the development, manufacturing, and marketing of pharmaceutical products and vaccines. The company is dedicated to improving health outcomes through innovative research and is known for its focus on areas such as oncology, infectious diseases, and immunology. In addition to its pharmaceutical offerings, Merck actively engages in the discovery of new biologics and therapies, working to address some of the most pressing health challenges worldwide. Through its commitment to scientific excellence and patient care, Merck plays a critical role in advancing public health and enhancing quality of life globally. Read More
As of mid-November 2025, a palpable unease has settled over the technology sector, long the darling of investors and the primary engine of market growth. After a period of unprecedented outperformance, particularly by companies at the forefront of artificial intelligence (AI), tech stocks are now experiencing a noticeable downturn. This
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Jannie Oosthuizen, president, Human Health U.S., and Dr. Marjorie Green, senior vice president and head of oncology, global clinical development, Merck Research Laboratories, are scheduled to participate in a fireside chat at the Jefferies Global Healthcare Conference in London on Thursday, Nov. 20, 2025, at 9:30 a.m. ET / 2:30 p.m. GMT.
Washington D.C. – November 12, 2025 – Looking back from today, the critical period following a hypothetical, yet highly plausible, U.S. government shutdown in late 2024 served as a stark reminder of the indispensable role of timely economic data. As federal agencies grappled with reopening, the U.S. Labor Department
The Nasdaq Composite (NASDAQ: IXIC) experienced back-to-back losses on November 11 and 12, 2025, signaling a significant recalibration in the financial markets. This downturn, primarily driven by growing concerns over stretched valuations in the artificial intelligence (AI) sector and a pronounced rotation of capital into more traditional industries, marks a
New York, NY – November 12, 2025 – The Dow Jones Industrial Average (DJIA) has shattered previous records, closing at an all-time high of 48,254.82 today, marking a significant milestone for the venerable index. This historic surge, following another record close yesterday, injects a palpable sense of optimism into the
The financial markets are currently exhibiting an extraordinary and complex phenomenon: both traditional safe-haven assets, gold and silver, are experiencing robust rallies, while the Dow Jones Industrial Average (DJIA) has simultaneously surged past the 48,000-point mark. As of November 12, 2025, gold prices are trading around $4,105-$4,
New York, NY – November 12, 2025 – In a remarkable display of market resilience and underlying tension, the Dow Jones Industrial Average (DJIA) has surged past the 48,000-point threshold, closing at an unprecedented 48,015.79. This historic equity rally is unfolding concurrently with a robust ascent in precious metals,
The Dow Jones Industrial Average (DJIA) made history on Wednesday, November 12, 2025, surging past the 48,000-point mark for the first time ever, gaining nearly 380 points. This significant rally was fueled by a wave of optimism surrounding the imminent resolution of a protracted U.S. government shutdown, which
NEW YORK, NY – November 11, 2025 – The Dow Jones Industrial Average (DJIA) has reached an unprecedented milestone today, soaring to a new all-time high of 47,927.96, a robust gain of 559.33 points (1.2%). This marks the 16th record close for the index this year, sending a
New York, NY – November 11, 2025 – The Dow Jones Industrial Average (DJIA) has today surged to an unprecedented all-time high, pushing past significant milestones and reinforcing a complex, yet largely optimistic, sentiment across the financial markets. This monumental achievement signals a robust, albeit cautious, wave of investor confidence, underpinned by
A number of stocks jumped in the afternoon session after the market experienced a sharp sector rotation, as investors fled growth-oriented technology stocks and piled into value-oriented names amid growing valuation concerns. This divergence was stark: the tech-heavy Nasdaq struggled, losing 0.2%, while the Dow rallied.
This shift away from tech was triggered by a series of negative catalysts in the AI sector. AI cloud provider CoreWeave slid on disappointing guidance, while chip darling Nvidia pulled back after SoftBank sold its stake. This "hurt the AI trade," dragging down related names like Micron and Oracle.
As capital left tech, it sought safety in "higher quality" defensive names. Health care giants like Merck, Amgen, and Johnson & Johnson saw significant buying, boosting the Dow.
Let's have a look at what is happening on the US markets in the middle of the day on Tuesday. Below you can find the top S&P500 gainers and losers in today's session.
New York, NY – November 10, 2025 – The S&P 500 Healthcare sector presented a mixed picture today, with the broader index showing a modest uptick while significant segments, particularly health insurers and some providers, faced considerable downward pressure. This divergence highlights a sector grappling with a flurry of groundbreaking drug
New York, NY – November 10, 2025 – In a financial landscape often characterized by extremes, Cliff Asness, the influential co-founder of AQR Capital Management, offers a nuanced yet stark assessment of the current stock market: it is undeniably expensive, but crucially, it does not fit his stringent definition of a bubble.
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of results from the pivotal Phase 3 CORALreef HeFH trial demonstrating that treatment with enlicitide decanoate, an investigational, once-daily oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, resulted in a statistically significant and clinically meaningful reduction in low-density lipoprotein cholesterol (LDL-C) of 59.4% compared to placebo at week 24 (95% CI: -65.6, -53.2; p<0.001) in adults with heterozygous familial hypercholesterolemia (HeFH). The effect size and safety profile was comparable to that observed in the pivotal Phase 3 CORALreef Lipids study. These late-breaking data will be presented for the first time today at the American Heart Association (AHA) Scientific Sessions 2025 (Abstract #4391641) and published simultaneously in the Journal of the American Medical Association.
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of results from the pivotal Phase 3 CORALreef Lipids trial demonstrating that treatment with enlicitide decanoate, an investigational, once-daily oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, resulted in a statistically significant and clinically meaningful reduction in low-density lipoprotein cholesterol (LDL-C) of 55.8% (primary analysis; 95% CI: -60.9, -50.7; p<0.001) and of 59.7% in a post-hoc reanalysis (95% CI: -62.3, -57.1; p<0.001) compared to placebo at week 24. These late-breaking data will be presented for the first time today at the American Heart Association (AHA) Scientific Sessions 2025 (Abstract #4391578) and were selected for the Late-Breaking Science News Briefing.
The biotech sector is currently experiencing a robust rally, a significant turnaround from a period of subdued performance. This resurgence is primarily fueled by a wave of promising drug trial results that are validating extensive research and development efforts across the industry. Investors are demonstrating a renewed appetite for risk,
